Journal: Frontiers in Pharmacology
Article Title: Targeting GIRK Channels for the Development of New Therapeutic Agents
Figure Lengend Snippet: Expression of GIRK channels in AtT20 cells . Left panel: Currents were measured before (control) and after the addition of somatostatin (200 nM) during voltage steps applied from the holding potential of −40 to −60, −80, and −100 mV. Addition of tertiapin (500 nM) inhibited the current (bottom records). The solid lines represent zero current. Top right panel: I/V relationship for the somatostatin activated current (Som) displayed inward rectification and a reversal potential of −40 mV. Current values were obtained by subtracting the currents by records obtained in the presence of 1 mM BaCl 2 . Each point represents the mean ± SE current (pA/pF) measured in three to five cells. Bottom right panel: dose versus response curve for tertiapin-Q block of the AtT20 cell GIRK current. Each point represents the mean ± SE inhibition obtained from three to six experiments. The calculated IC 50 value for tertiapin-Q block was 60 nM.
Article Snippet: Drugs and chemicals Carbachol, somatostatin, and a Na+ , K+ channel modulator kit (catalog # LO2220), containing 68 compounds, were purchased from Sigma-Aldrich Chemical Corp. Tertiapin-Q (synthetic formulation) was obtained from Alomone Labs.
Techniques: Expressing, Blocking Assay, Inhibition